poisar

Stocks · News reference

GSK Wins FDA Approval For Jideytro To Treat Previously Treated ROS1-Positive Non-Small Cell Lung Cancer

BenzingaJul 22, 2026, 4:41 PMBenzinga Newsdesk

GSK plc (LSE/NYSE:GSK) today announced the US Food and Drug Administration (FDA) has approved Jideytro (zidesamtinib), a ROS1 selective inhibitor, for the treatment of adult patients with locally advanced or metastatic

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
benzinga
Observed
Jul 22, 2026, 4:41 PM
Checked
Jul 22, 2026, 4:41 PM
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading